By Brad Sorensen, CFA
NASDAQ: COSM
READ THE FULL COSM RESEARCH REPORT
We view Cosmos Health’s (NASDAQ: COSM) latest launch of C-ScrubVet as an intriguing extension of the company’s strategy of using its existing manufacturing, regulatory, distribution, and brand infrastructure to enter additional healthcare markets without having to build an entirely new business from scratch. The veterinary antimicrobial product takes an established Cosmos Health platform and extends it into a global animal health industry that is large, growing, and increasingly focused on preventive care. For investors, we believe the significance of the announcement goes beyond the potential sales of a single product: C-ScrubVet provides another example of Cosmos attempting to extract more value from assets it already owns while broadening its addressable market.
Cosmos Health is quickly developing into a vertically integrated healthcare platform rather than operating simply as a pharmaceutical distributor. Its businesses encompass pharmaceutical distribution, contract manufacturing, proprietary pharmaceutical and nutraceutical brands, healthcare products, telehealth and research and development. The company's principal brands include Sky Premium Life, C-Sept and C-Scrub, while its Cana Laboratories subsidiary gives Cosmos an important in-house manufacturing capability. Cana operates an EU GMP-licensed and EMA-certified facility capable of producing pharmaceuticals, supplements, cosmetics, biocides and medical devices. Cosmos also has pharmaceutical distribution operations in Greece through CosmoFarm and a growing UK presence through Decahedron.
That vertical integration is particularly relevant to the C-ScrubVet story. Cosmos announced that it has received its first orders for C-ScrubVet, its veterinary antimicrobial line, with commercial sales beginning in the United Kingdom. C-ScrubVet Wash 4% CHDG contains 4% chlorhexidine digluconate and is designed as an antimicrobial cleanser effective against bacteria, fungi and enveloped viruses. The product is intended for dogs, cats, horses, companion animals, and large animals and is being introduced in a 500ml pump-dispenser bottle. Importantly, it has been certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary applications.
We believe the fact that Cosmos has already received initial orders is important. Earlier this year, the veterinary opportunity was largely a development and expansion concept. The latest announcement moves C-ScrubVet into the commercialization phase. Sales are beginning in the UK, with Cosmos planning additional European markets beginning in the fourth quarter of 2026. Initially, the company intends to emphasize e-commerce before expanding into pet-store chains and veterinary clinics.
From an investment standpoint, one of the most attractive aspects of the launch is that Cosmos is not starting from zero. C-ScrubVet is derived from the company's existing C-Scrub Wash 4% platform. The company already possesses manufacturing infrastructure, formulation experience, testing and quality-control systems, and commercial experience with the C-Scrub brand. Production takes place internally at Cana Laboratories. This potentially reduces both the cost and execution risk associated with entering a completely new product category.
C-Scrub itself has been making meaningful commercial and regulatory progress. The human-use product successfully passed EN 12791 clinical validation for surgical hand disinfection, opening hospital and surgical applications, while Cosmos has also expanded the brand through online and retail channels in the UK. The veterinary version therefore becomes another way to monetize a formulation, brand, and manufacturing infrastructure that Cosmos has already invested in creating.
The market Cosmos is entering is substantial. Grand View Research estimates the overall global animal health market at approximately $68.7 billion in 2025, rising to $75.3 billion in 2026 and potentially reaching $156 billion by 2033, representing an estimated compound annual growth rate of approximately 11%. Growth is being supported by higher animal-health spending, greater attention to diseases, increased pet insurance penetration, changing regulations, and the continuing trend toward treating companion animals as members of the family.
The companion-animal portion of the market is particularly interesting for C-ScrubVet. Grand View estimates the global companion animal health market at $25.5 billion in 2025 and $27.9 billion in 2026, with the market potentially reaching $56.4 billion by 2033. Dogs accounted for approximately 40% of the market in 2025. Other recent industry estimates similarly point toward sustained growth in spending on veterinary pharmaceuticals and preventive animal healthcare.
We see several structural reasons this market could remain attractive. Pet ownership and the "humanization" of pets have increased owners' willingness to spend on animal health. At the same time, veterinary clinics are placing greater emphasis on infection prevention and preventive healthcare. The livestock side of the market creates another potentially large opportunity because animal health and hygiene can have direct economic consequences for producers through disease prevention, animal productivity, and food-supply protection. Research and Markets estimates that the broader animal health market could expand from roughly $52.4 billion in 2025 to $71.8 billion by 2030 under its somewhat more conservative market definition.
For Cosmos, however, the key issue is not whether it captures a large percentage of a $69 billion-plus market. It does not need to. Given Cosmos Health's current size, even a very small share of the veterinary antimicrobial and hygiene opportunity could become financially meaningful. The more important question will be whether management can use its existing UK and European distribution relationships to establish C-ScrubVet efficiently and then expand the brand into veterinary clinics, pet retailers and additional countries.
This is where we see the launch fitting in exceptionally well with the broader Cosmos strategy. Management has increasingly pursued a "platform" approach in which the company's manufacturing and distribution infrastructure supports multiple products and revenue streams. Cana Laboratories manufactures both for Cosmos and third parties. CosmoFarm distributes through an expanding pharmacy network. Decahedron provides an established UK presence. Cosmos is simultaneously expanding proprietary brands such as Sky Premium Life and C-Scrub while developing its 18 Series of clinically supported nutraceutical products for the U.S. market. C-ScrubVet adds animal health without requiring Cosmos to abandon or materially alter this infrastructure.
The veterinary expansion illustrates the potential economic value of vertical integration. A company that simply owned a consumer healthcare brand might need to outsource formulation, manufacturing, regulatory work, and distribution when entering a new category. Cosmos already controls many of those functions. C-ScrubVet is manufactured at Cana, can leverage the C-Scrub formulation and quality systems, and can initially use e-commerce and the company's existing UK presence before moving into more specialized veterinary channels. If sales scale, the incremental economics could therefore become more attractive because much of the underlying infrastructure already exists.
The timing also appears favorable because the veterinary launch is occurring against a backdrop of accelerating growth in Cosmos's core operations. Second-quarter 2026 revenue reached a record $18.99 million, up 28.8% year over year, while first-half revenue increased 29.7% to $36.91 million. Adjusted Q2 gross profit increased 58.4%, and adjusted gross margin expanded 165 basis points to 9.54%. Operating expenses increased only 16.5% during the quarter, substantially slower than revenue growth, providing evidence of improving operating leverage.
We believe the C-ScrubVet launch strengthens the longer-term COSM investment story. It demonstrates a potentially repeatable model: develop or acquire an asset, manufacture it internally, obtain the necessary certifications, distribute it through existing channels, and then extend the product into additional geographies and market categories. In this case, Cosmos has effectively taken an antimicrobial platform developed for human healthcare and created an entry point into a global animal-health market approaching $70 billion and growing at an attractive rate.
The opportunity becomes especially interesting when viewed alongside Cosmos Health's other initiatives. The company is simultaneously expanding pharmaceutical distribution, building Cana's contract manufacturing backlog, growing proprietary nutraceutical brands, entering the U.S. with its 18 Series, expanding C-Scrub into hospital and surgical settings, and now commercializing C-ScrubVet in animal health. Management has established ambitious 2029 targets of approximately $200.6 million in revenue and $44.2 million in adjusted EBITDA. C-ScrubVet is specifically identified by the company as one of several potential catalysts supporting that longer-term outlook.
We see the reason investors should consider COSM as increasingly based on the cumulative effect of multiple growth engines rather than the success of any single product. C-ScrubVet by itself is unlikely to transform Cosmos overnight, and investors should not assume that the enormous size of the animal-health market automatically translates into significant COSM revenue. What makes the launch attractive to us is the relatively capital-efficient manner in which Cosmos appears to be entering the market. It is leveraging an existing formulation, an existing brand, existing certifications and regulatory capabilities, an established UK commercial presence and, most importantly, its own manufacturing facility.
For investors willing to accept the considerable execution and small-cap risks, the C-ScrubVet launch is another encouraging piece of evidence that Cosmos Health's collection of manufacturing, distribution and proprietary-brand assets can be used as a unified growth platform. The immediate revenue contribution may initially be modest, but the strategic importance is considerably larger: Cosmos has opened a new commercial vertical in a rapidly expanding global healthcare market while utilizing infrastructure it already owns. If initial UK sales translate into broader European distribution and eventual penetration of veterinary and retail channels, C-ScrubVet could develop into another meaningful contributor to Cosmos Health's increasingly diversified growth story, and we believe worth serious consideration by investors.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.